.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Harvard Business School
Mallinckrodt
Queensland Health
Fish and Richardson
US Department of Justice
AstraZeneca
Healthtrust
Accenture
Novartis

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,030,330

« Back to Dashboard

Which drugs does patent 8,030,330 protect, and when does it expire?


Patent 8,030,330 protects EVISTA and is included in one NDA.

This patent has forty-three patent family members in thirty-three countries.

Summary for Patent: 8,030,330

Title:Benzothiophenes, formulations containing same, and methods
Abstract: This invention provides compounds of formula I ##STR00001## and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
Inventor(s): Arbuthnot; Gordon Nelson (Indianapolis, IN), Dalder; Brian Weston (West Lafayette, IN), Hartauer; Kerry John (Carmel, IN), Luke; Wayne Douglas (West Lafayette, IN), Stratford, Jr.; Robert Eugene (Carmel, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:12/757,395
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
LillyEVISTAraloxifene hydrochlorideTABLET;ORAL020815-001Dec 9, 1997ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,030,330

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,458,811 Benzothiophenes formulations containing same and methods► Subscribe
6,894,064 Benzothiophenes, formulations containing same, and methods► Subscribe
6,797,719 Benzothiophenes, formulations containing same, and methods► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,030,330

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel140742► Subscribe
Japan2000507268► Subscribe
Japan2009019057► Subscribe
Japan2013166797► Subscribe
Japan2015157865► Subscribe
Japan2016106159► Subscribe
South Korea20000004962► Subscribe
MontenegroP18308► Subscribe
Malaysia115533► Subscribe
Norway984444► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Cantor Fitzgerald
Argus Health
Citi
Boehringer Ingelheim
McKesson
Daiichi Sankyo
Novartis
Fuji
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot